Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357954 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL5352197 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL13431000 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL3230032 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL5354673 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL5350282 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL5351714 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL11713345 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL5355662 | 0.98 | DGKA (0.66) | DGKALTA4HTP53TSHRFAAH | |
| SCHEMBL21834924 | 0.95 | LTA4H (0.56) | DGKALTA4HTSHRTHRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117223117-A | Component for use in an energy storage device or an energy conversion device and method for producing the same | 伊利卡科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-2165696-A1 | Cosmetic and dermatological formulations containing phenoxyalkyl esters | Evonik Goldschmidt GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| US-20100068160-A1 | COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING PHENOXYALKYL ESTERS | EVONIK GOLDSCHMIDT GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20100068160-A1 | COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING PHENOXYALKYL ESTERS | EVONIK GOLDSCHMIDT GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
| US-20100068160-A1 | COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING PHENOXYALKYL ESTERS | EVONIK GOLDSCHMIDT GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068160-A1 | COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING PHENOXYALKYL ESTERS | CUTA, DECR2, TYR | DGKA 702/4885LTA4H 255/4885TP53 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.